英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
fique查看　fique　在百度字典中的解释百度英翻中〔查看〕
fique查看　fique　在Google字典中的解释Google英翻中〔查看〕
fique查看　fique　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • How We Treat Metastatic Castration-Sensitive Prostate Cancer
    Prostate cancer (PC) is the second most common neoplasm in men worldwide and the most common in the United States The number of new cases has been steadily increasing over the last decade and is estimated to impact 299,010 Americans in 2024, with the number of metastatic cases nearly doubling from 3 9% to 8 2% More than 35,000 men are estimated to die of prostate cancer in 2024, representing
  • Metastatic Castration-Sensitive Prostate Cancer: Optimizing . . .
    Prostate cancer accounts for one in every five cancer diagnoses, making it the most common cancer in men, and metastatic prostate cancer is the second most common cause of cancer-related deaths in men in the United States 1 The incidence of prostate cancer began to decline in 2000, and it has more rapidly declined since the U S Preventive
  • Metastatic Castration-Sensitive Prostate Cancer (mCSPC . . .
    Panelists discuss how metastatic castration-sensitive prostate cancer (mCSPC) is managed with a combination of androgen deprivation therapy, chemotherapy, and novel agents like such as abiraterone and enzalutamide, aiming to improve survival outcomes while addressing the disease's high metastatic burden
  • Metastatic castration-resistant prostate cancer (mCRPC)
    Symptoms Metastatic castration-resistant prostate cancer doesn't always cause symptoms at first This cancer happens when prostate cancer spreads and no longer responds to hormone therapy treatments Sometimes it's found with blood tests or imaging tests before it causes symptoms Having a prostate cancer that is castration resistant doesn't cause specific symptoms Symptoms typically happen
  • Advanced and metastatic prostate cancer: ESMO Clinical . . .
    This ESMO Clinical Practice Guideline (CPG) focuses on advanced and metastatic prostate cancer This includes metastatic castration-sensitive prostate cancer (mCSPC), non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic castration-resistant prostate cancer (mCRPC) The management of early-stage disease is covered in the ESMO CPG for local and locoregional prostate cancer 1
  • Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer
    The initial treatment for metastatic prostate cancer is androgen-deprivation therapy (ADT) through medical or surgical castration
  • Prognostic Impact of Time to Castration Resistance on Overall . . .
    1 Introduction Prostate cancer (PC) is the most commonly diagnosed cancer in men and the leading cause of cancer-related deaths in developed countries [1] Approximately 10% of patients with distant metastases upon diagnosis are classified as having metastatic castration-sensitive prostate cancer (mCSPC) [2]
  • Real-World Treatment Patterns and Survival in People With . . .
    To examine treatment patterns and survival in people with metastatic castration-resistant prostate cancer (mCRPC) previously progressing from metastatic hormone-sensitive prostate cancer (mHSPC) in the United States
  • Strategic Advances in Combination Therapy for Metastatic . . .
    The contemporary treatment for metastatic castration-sensitive prostate cancer (mCSPC) has evolved significantly, building on successes in managing metastatic castration-resistant prostate cancer (mCRPC) Although androgen deprivation therapy (ADT) alone has long been the cornerstone of mCSPC treatment, combination therapies have emerged as the new standard of care based on recent advances
  • Docetaxel Rechallenge vs Cabazitaxel in Patients With . . .
    This cohort study compares overall survival in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel or docetaxel rechallenge after initial treatment with docetaxel





中文字典-英文字典  2005-2009